Apellis Pharmaceuticals -- The Essentials

Mid-cap Health Care company Apellis Pharmaceuticals has moved 1.1% so far today on a volume of 249,106, compared to its average of 5,163,615. In contrast, the S&P 500 index moved 0.0%.

Apellis Pharmaceuticals trades -37.28% away from its average analyst target price of $71.57 per share. The 14 analysts following the stock have set target prices ranging from $38.0 to $95.0, and on average have given Apellis Pharmaceuticals a rating of buy.

If you are considering an investment in APLS, you'll want to know the following:

  • Apellis Pharmaceuticals has moved -22.0% over the last year, and the S&P 500 logged a change of 23.0%

  • Based on its trailing earnings per share of -6.29, Apellis Pharmaceuticals has a trailing 12 month Price to Earnings (P/E) ratio of -7.1 while the S&P 500 average is None

  • APLS has a forward P/E ratio of -20.3 based on its forward 12 month price to earnings (EPS) of $-2.21 per share

  • The company has a price to earnings growth (PEG) ratio of -0.3 — a number near or below 1 signifying that Apellis Pharmaceuticals is fairly valued compared to its estimated growth potential

  • Its Price to Book (P/B) ratio is 15.28 compared to its sector average of None

  • Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases.

  • Based in Waltham, the company has 767 full time employees and a market cap of $5.29 Billion.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.